UK Medicines Switch Applications (POM - P – GSL Reclassification)
Key insights
- Why companies choose to switch. The requirements and outline of the process for a medicine reclassification in the UK, and dossier content for each type of application.
- Candidate selection criteria. The benefit-risk approach and considerations for a Scientific Advice Meeting.
- Non-regulatory considerations, naming, and exclusivity post-switch.
Access the recording
Connect with our team
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.